{
  "id": "63f032caf36125a42600001a",
  "type": "summary",
  "question": "What is the mechanism of action of rilzabrutinib?",
  "ideal_answer": "Rilzabrutinib is oral Bruton tyrosine kinase (BTK) inhibitor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35302767",
    "http://www.ncbi.nlm.nih.gov/pubmed/36182620",
    "http://www.ncbi.nlm.nih.gov/pubmed/35301810"
  ],
  "snippets": [
    {
      "text": "This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35302767",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Herein, we describe the design of covalent reversible BTK inhibitors and the discoveries of PRN473 (11) and rilzabrutinib (PRN1008, 12). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35302767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ongoing trials include new B-cell/plasma-cell targeting agents such as the Bruton tyrosine kinase inhibitors ibrutinib and rilzabrutinib, and the anti-CD38 MoAbs daratumumab and its analogue isatuximab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36182620",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}